Post

Where do anti-tumor necrosis factor like cytokine agents go now?

In the past few months, significant interest within the inflammatory bowel disease (IBD) space has been directed towards the therapeutic …

Pharma’s engagement with healthcare providers has slipped in recent years

In recent years there has been a downward trend in health care provider (HCP) contact in the pharmaceutical industry with …

Amgen and MSD-backed start-up wins $10m for drug and device development

Culmination Bio has secured $10m in investment from the Merck Global Health Innovation Fund (venture capital arm of MSD) and …

CTO Europe 2023: EU’s IVD guidelines continue affecting early clinical work

The implementation of the In Vitro Diagnostic Medical Devices Regulation (IVDR) by the European Union (EU) continues to be a …

Waning focus on abuse potential may negatively affect pipeline non-stimulants for ADHD

The use of stimulants for attention deficit hyperactivity disorder (ADHD) treatment is increasing. Despite this, three out of the four …